07/08/2019 SOURCE: www.fiercebiotech.com
Pfizer and Sangamo Therapeutics have shared an upbeat update on their hemophilia A gene therapy. The update features evidence of the durability of responses to SB-525 and an early look at results in two recently-treated patients, adding to the impression that the gene therapy is a threat to assets including BioMarin’s valrox and Spark Therapeutics’ SPK-8011New data boost Pfizer, Sangamo hemophilia A gene therapy
-
(0)
-
Bookmark
- Comments. (0)
07/08/2019 SOURCE: www.fiercebiotech.com
Two months after Merck announced a billion-dollar plus deal to buy out late-stage cancer biotech Peloton, some of its staffers are finding new homes. Skyhawk Therapeutics nabs Peloton exec and cancer R&D veteran as VP of oncology biology
-
(0)
-
Bookmark
- Comments. (0)
Chris Feix
Topics: Pesticides, Beekeeping, Pest Control, Government / Policies,
-
(1)
-
Bookmark
- Comments (0)
Brandon Lance
-
(1)
-
Bookmark
- Comments (0)
-
(0)
-
Bookmark
- Comments (0)
Randy Krotz
-
(2)
-
Bookmark
- Comments (0)
Randy Krotz
-
(2)
-
Bookmark
- Comments (0)
Randy Krotz
-
(2)
-
Bookmark
- Comments (0)
John LaRose Jr.
